Drug Trial Radar · NCT06003751
A Study of PER-001 in Participants With Diabetic Retinopathy
Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Aug 5, 2023
Primary completion
Apr 3, 2025
Study completion Dec 10, 2025
Sponsor
- Lead sponsor
- Perfuse Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.
Conditions
- Diabetic Retinopathy
Interventions
PER-001 Intravitreal Implant - Low DoseDrug
PER-001 Low Dose Intravitreal Implant
PER-001 Intravitreal Implant - High DoseDrug
PER-001 High Dose Intravitreal Implant
PER-001 Intravitreal Implant - ShamDrug
PER-001 Intravitreal Sham
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best-corrected Visual Acuity (BCVA)Time frame: End of Study(Week 24)
- Intraocular Pressure (IOP)Time frame: End of Study(Week 24)
- Ocular Adverse eventsTime frame: End of Study(Week 24)
- Systemic Adverse eventsTime frame: End of Study(Week 24)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Perfuse Therapeutics, Inc
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.